The estimated Net Worth of Ashish Mandelia is at least $69.6 ezer dollars as of 13 January 2024. Mr Mandelia owns over 12,780 units of Mersana Therapeutics Inc stock worth over $50,185 and over the last 5 years he sold MRSN stock worth over $19,421.
Mr has made over 7 trades of the Mersana Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 12,780 units of MRSN stock worth $22,621 on 13 January 2024.
The largest trade he's ever made was exercising 12,780 units of Mersana Therapeutics Inc stock on 13 January 2024 worth over $22,621. On average, Mr trades about 3,742 units every 143 days since 2020. As of 13 January 2024 he still owns at least 28,353 units of Mersana Therapeutics Inc stock.
You can see the complete history of Mr Mandelia stock trades at the bottom of the page.
Ashish Mandelia is the VP, Controller & Principal Accounting Officer at Mersana Therapeutics Inc.
Mr Mandelia is 47, he's been the VP és Controller & Principal Accounting Officer of Mersana Therapeutics Inc since . There are 14 older and 4 younger executives at Mersana Therapeutics Inc. The oldest executive at Mersana Therapeutics Inc is Lawrence Alleva, 70, who is the Independent Director.
Ashish's mailing address filed with the SEC is C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Over the last 7 years, insiders at Mersana Therapeutics Inc have traded over $1,068,087 worth of Mersana Therapeutics Inc stock and bought 26,457,775 units worth $226,822,416 . The most active insiders traders include Forest Baskett, Scott D Sandell és Anthony A. Jr. Florence. On average, Mersana Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $534,621. The most recent stock trade was executed by Anna Protopapas on 13 January 2024, trading 86,958 units of MRSN stock currently worth $153,916.
mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.
Mersana Therapeutics Inc executives and other stock owners filed with the SEC include: